Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid)

The active ingredient consists of the group C capsular polysaccharide chemically linked to tetanus toxoid. This conjugation converts the polysaccharide into a T‑cell‑dependent antigen, prompting helper T‑cell activation, which drives a strong B‑cell response and the production of high‑affinity antibodies that target the bacterial capsule.

The dosing regimen for Neisvac‑C is determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunisation guidelines. The prescriber will specify the number of doses, interval between doses, and any booster requirements.

Safety data for Neisvac‑C in pregnancy and lactation are limited. The vaccine should only be used when the potential benefit to the mother outweighs any uncertain risk to the fetus or infant. Healthcare providers should discuss individual circumstances with the patient.

To order Neisvac‑C, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Neisvac‑C is a monovalent group C conjugate vaccine, whereas some alternatives, such as quadrivalent conjugate vaccines, protect against additional serogroups (A, W, Y). Neisvac‑C offers a focused immune response to serogroup C and may be preferred in settings where that serogroup predominates or when a single‑serogroup formulation is required.

Neisvac‑C must be stored refrigerated at 2 °C to 8 °C. It should be kept in the original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

Neisvac‑C is supplied as an injectable solution for intramuscular injection, typically into the deltoid muscle. The administration is performed by a qualified healthcare professional using aseptic technique, following the dosing schedule prescribed for the individual patient.

The most serious adverse events reported with Neisvac‑C include severe allergic reactions such as anaphylaxis and, rarely, Guillain‑Barré syndrome. Immediate medical attention is required if signs of a severe allergic reaction occur, and patients should be observed after vaccination according to standard practice.

Neisvac‑C should not be given to individuals with a known hypersensitivity to any component of the vaccine, including the tetanus toxoid carrier. It is also contraindicated in persons who have experienced a severe allergic reaction to a previous dose of the same vaccine.